Activist lifts Clariant stake, aiming to scuttle
Huntsman deal
Send a link to a friend
[September 19, 2017]
By Joshua Franklin and John Miller
ZURICH (Reuters) - The activist investor
fighting Clariant's planned $20 billion merger with Huntsman Corp has
built a 15.1 percent stake in the Swiss chemicals maker, making it the
company's biggest shareholder.
In a letter to Clariant's board of directors, White Tale Holdings, a
vehicle created by investor Keith Meister's Corvex hedge fund and New
York's 40 North, underscored its opposition to the Huntsman deal.
"Unfortunately, we remain convinced, and increasingly so, that the
proposed merger is detrimental to Clariant shareholders," it said in the
letter published on Tuesday.
"It both significantly destroys existing Clariant shareholder value and
prevents Clariant from pursuing multiple alternative and immediate
opportunities to unlock value for its shareholders."
The investor, which said it was open to joining Clariant's board, said
alternatives included selling its plastics and coatings unit, which
accounts for 43 percent of the company's 5.8 billion Swiss francs ($6
billion) in annual revenue.
Clariant is the latest company to have its plans challenged by an
activist investor, with global companies including Nestle <NESN.VX> and
BHP Billiton <BLT.L> both facing criticism.
Clariant shares rose 0.3 percent in early trading, bringing their gain
since just before the merger was announced on May 22 to 14 percent.
Huntsman shares have risen 7.3 percent.
In July, Clariant said White Tale Holdings held "in excess of 10
percent" of shares.
Clariant and Huntsman in May announced a merger valued at around $20
billion including debt in which Clariant shareholders would hold 52
percent of the combination.
They talked up prospects for faster growth for the combined company as
rationale for "a merger of equals". Among other things, they expect
about $400 million in annual cost synergies.
However, White Tale, which made public its opposition in July, said
around 300 million Swiss francs of these savings could be achieved by
Clariant alone.
"The terms of the proposed merger significantly undervalue Clariant's
shares while they simultaneously overvalue Huntsman at the peak of its
cyclical commodity business cycle," White Tale said.
[to top of second column] |
The logo of Swiss specialty chemicals company Clariant is seen at
the company's headquarters in Pratteln, Switzerland August 9, 2017.
REUTERS/Arnd Wiegmann
Clariant said on Tuesday it was preparing a response.
Kepler Cheuvreux analyst Christian Faitz, rejected White Tale's criticism.
"White Tale’s suggestions are naïve, in our view," he said. "Real life in the
chemical industry is not planned on a consultant or banker flip chart."
In a newspaper interview published this month, Huntsman Chief Executive Peter
Huntsman said shareholders in Clariant and his own company "almost without
exception" supported the deal after learning the rationale.
Two-thirds of Clariant shareholders must back the merger at a special meeting
for it to proceed. The date has yet to be set, with Clariant CEO Hariolf
Kottmann saying he would only schedule it after regulators approve the deal.
At the Swiss company's last annual shareholder meeting in March, however,
investors representing only 53 percent of the share capital voted.
At that participation level, White Tale would have just shy of 30 percent of the
votes and would need only a limited number of allies to halt the deal.
However, it is likely turnout at the next meeting will be higher. To that end,
Kottmann has been meeting investors, including at the Dorchester Hotel in London
this month, to convince them of the transaction's merits.
A person close to the matter said Clariant's second-largest investor, a group of
Bavarian families who hold about 14 percent of the shares, remained "fully
supportive" of the merger.
($1 = 0.9604 Swiss francs)
(Additional reporting by Arno Schuetze in Frankfurt; Editing by Michael Shields
and Mark Potter)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |